Abstract
This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second generation selective and reversible MAOIs such as the MAO-A inhibitor, moclobemide and the MAO-B inhibitor, selegiline. Data for review were identified from a literature search of OvidSP Medline and PsycInfo performed in July 2012, using the subject terms and keywords of ‘monoamine oxidase inhibitors’, ‘major depression’, ‘depressive disorder’ and ‘depression (emotion)’. The search was limited to papers published in the English language and from 2007 onward only.
Irreversible MAOIs have the potential to treat the most challenging mood disorder patients including those with treatment-resistant depression, atypical depression and bipolar depression. Unfortunately, the use of irreversible MAOIs has been declining sharply due to lack of marketing and the excessive fears of clinicians. Moreover, few clinicians now have any experience, let alone comfort, in prescribing this class of antidepressants. The newer MAOIs are available as another option for the treatment of major depression but have not replaced the irreversible MAOIs for the specific sub-types of depression for which they are now recommended in most consensus guidelines and treatment algorithms.
The pharmacology, drug interactions and dietary recommendations associated with the use of MAOIs are reviewed. With the appropriate dietary restrictions and attention to potential drug interactions with serotonin and noradrenaline agents this class of drugs can be used effectively and safely. The MAOIs still represent an important element in our therapeutic armamentarium. Despite recommendations by opinion leaders and consensus guidelines for the use of MAOIs in specific sub-types of depression, the prescription rate of MAOIs is far less than expected and is decreasing. The “bad reputation” and the lack of industry support for this class of agents (especially the irreversible MAOIs) must be overcome in order to continue to provide a potentially useful treatment for a very vulnerable yet substantial sub-population of mood disorder patients.
Similar content being viewed by others
References
Papakosta GI, Bech P, Fava M. Pharmacological treatment of major depressive disorder: a review, in depressive disorders. In: Herrmann H, Maj M, Sartorius N, editors. New York: Wiley; 2009. p. 47–74.
Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563–86.
Shih JC, Chen K. Regulation of MAO-A and MAO-B gene expression. Curr Med Chem. 2004;11(15):1995–2005.
Kalgutkar AS, Dalvie DK, Castagnoli N Jr, et al. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–62.
Andres N, Lizcano JM, Rodriguez MJ, et al. Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem. 2001;49(2):209–17.
Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology. 2004;25(1–2):139–48.
Lewinsohn R, Glover V, Sandler M. Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: a source of some anomalies? Biochem Pharmacol. 1980;29(5):777–81.
Campbell IC, Marangos PJ, Parma A, et al. Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases. Neurochem Res. 1982;7(6):657–66.
Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol. 2011;100:169–90.
Bieck PR, Firkusny L, Schick C, et al. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther. 1989;45(3):260–9.
Tiller JW, Maguire KP, Davies BM. Tyramine pressor response with moclobemide—a reversible monoamine oxidase inhibitor. Psychiatry Res. 1987;22(3):213–20.
Sunderland T, Mueller EA, Cohen RM, et al. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl). 1985;86(4):432–7.
Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434–41.
Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859–82.
Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46(3 Pt 2):14–9.
Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991;337(8735):246.
Boakes AJ, Laurence DR, Teoh PC, et al. Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973;1(5849):311–5.
Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31(1):66–74.
Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet. 1963;2(7313):849–50.
Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry. 1984;29(8):707–11.
Shulman KI, Walker SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397–402.
Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(Suppl 8):35–41.
Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185–219.
Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry. 1989;46(9):783–6.
Robinson DS, Nies A, Davis JN, et al. Ageing, monoamines, and monoamine-oxidase levels. Lancet. 1972;1(7745):290–1.
Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209–16.
Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry. 1993;54(Suppl):10–4 Discussion 15.
Parker G, Roy K, Mitchell P, et al. Atypical depression: a reappraisal. Am J Psychiatry. 2002;159(9):1470–9.
Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993;21:30–4.
Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006;141(1):89–101.
McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150(1):118–23.
Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53(1):5–11.
Fekadu A, Rane LJ, Wooderson SC, et al. Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry. 2012;201(5):369–75.
Hamani C, Temel Y. Deep brain stimulation for psychiatric disease: contributions and validity of animal models. Sci Transl Med. 2012;4(142):142rv8.
American Psychiatric Association. Practice guideline for the treatment of patients with major depression disorder, vol 167; (2010).
Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–43.
Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870–86.
Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–73 discussion 147.
Spijker J, Nolen WA. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand. 2010;121(3):180–9.
Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115(5):360–5.
Stewart JW. Treating depression with atypical features. J Clin Psychiatry. 2007;68(Suppl 3):25–9.
Preskorn SH. Results of the STAR*D study: implications for clinicians and drug developers. J Psychiatr Pract. 2009;15(1):45–9.
McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–41 quiz 1666.
Nolen WA, van den Broek WW, Birkenhager TK. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiatry. 2007;164(3):524 author reply 524.
Shulman KI, Fischer HD, Herrmann N, et al. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009;70(12):1681–6.
Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25(1–2):215–21.
Goodnick PJ. Seligiline transdermal system in depression. Expert Opin Pharmacother. 2007;8(1):59–64.
Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96.
Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3(1):5–43.
National Institute for Health and Clinical Excellence. Depression in adults: the treatment and management of depression in adults. 2009. http://www.nice.org.uk/nicemedia/live/12329/45888/45888.pdf.
Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226–47.
Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression—a meta-analysis of moclobemide studies. J Affect Disord. 1995;35(1–2):21–30.
Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994;32(3):169–77.
Sogaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol. 1999;13(4):406–14.
Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. Int Clin Psychopharmacol. 1997;12(4):183–93.
Nair NP, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord. 1995;33(1):1–9.
Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002;159(11):1869–75.
Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64(2):208–14.
Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67(9):1354–61.
Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006;26(6):579–86.
Fawcett J. Why aren’t MAOIs used more often? J Clin Psychiatry. 2009;70(1):139–40.
Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855–70.
O’Brien V. The monoamine oxidase inhibitor: relics reconsidered. Psychiatr Ann. 2011;41(3):176–83.
Goldberg JF, Thase ME. Monoamine oxidase inhibitors revisited: what you should know. J Clin Psychiatry. 2013;74(2):189–91.
Acknowledgments
Dr. Shulman is supported in part by the Lewar Chair in Geriatric Psychiatry. Dr. Shulman, Dr. Herrmann and Dr. Walker have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Shulman, K.I., Herrmann, N. & Walker, S.E. Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs 27, 789–797 (2013). https://doi.org/10.1007/s40263-013-0097-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-013-0097-3